Trial · NCT06678074
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events (safety and tolerability) | Day 1-29 | Treatment-emergent adverse events |
| Secondary | CCR2+ cell myocardial infiltration (optional) | 48 hours and Day 15 | Characterization of CCR2+ cell myocardial infiltration mean standard uptake value (SUVmean) and change from 48 hours measured by myocardial PET/CT imaging at Day 15 |
| Secondary | Biomarker C-Reactive Protein | Day 4, 15, 29 | Change from baseline |
| Secondary | Biomarker White Blood Cell Count | Day 4, 15, and 29 | Change from baseline |
| Secondary | Biomarker Fibrinogen | Day 4, 15, 29 | Change from baseline |
| Secondary | Biomarker Interleukin 6 | Day 4, 15, and 29 | Change from baseline |
| Secondary | Biomarker Interleukin-1 | Day 4, 15, and 29 | change from baseline |
| Secondary | Biomarker Troponin I | Day 4, 15, and 29 | change from baseline |
| Secondary | Single-cell RNASeq | Day 4, 15, and 29 | change from baseline |
| Secondary | Cardiac death or readmission for heart failure | Day 1-90 | * Cardiac death defined as death due to acute MI, sudden cardiac death, HF, stroke, cardiovascular procedure, cardiovascular hemorrhage, or other cardiovascular cause. * Heart failure readmission, defined as an event in which the patient is admitted to the hospital with a primary diagnosis of HF, the length of stay is at least 24 hours (or extends over a calendar date), the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF. |
| Secondary | Left Ventricular Ejection Fraction | Day 1, Day 90 | Change from baseline, measured by echocardiography |
| Secondary | N-terminal pro B-type natriuretic peptide | Day 90 | blood test measurement of heart failure |
| Secondary | New York Heart Association Class | Day 90 | Measurement of cardiac status |
| Secondary | Kansas City Cardiomyopathy Questionnaire | Day 90 | Patient-reported outcome measure of health status and function |
| Other | Pharmacokinetic profile of serum IC14 level, including serum half life and maximum serum concentration | baseline, 15 minutes, 6 hours, Day 4, Day 15, Day 22, Day 29 | Serum IC14 levels |
| Other | Pharmacodynamics | Day 22, Day 29 | Percent monocyte CD14 receptor occupancy |
| Other | Immunogenicity | baseline, Day 29, Day 90 | Anti-drug antibodies |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06678074/registered